Use of glycoprotein IIb-IIIa inhibitor for a thromboembolic complication during Guglielmi detachable coil treatment of an acutely ruptured aneurysm.
Thrombotic occlusion of the anterior communicating and right anterior cerebral arteries occurred during embolization of an acutely ruptured aneurysm of the anterior communicating artery. Traditional management, including superselective infusion of a fibrinolytic agent, was unsuccessful in reestablishing normal vessel patency. Therefore, an intravenous dose of abciximab was administered. Serial angiography showed that normal vessel patency was reestablished within 10 min. There were no adverse events related to abciximab administration, and the patient recovered from the procedure without neurologic deficit.
Ng
P P
PP
Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Western Australia.
Phatouros
C C
CC
Khangure
M S
MS
D000077284:Abciximab; D000208:Acute Disease; D000328:Adult; D017542:Aneurysm, Ruptured / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004621:Embolization, Therapeutic / Q000009:adverse effects* / Q000295:instrumentation*; D004867:Equipment Design; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D002532:Intracranial Aneurysm / Q000628:therapy*; D020766:Intracranial Embolism / Q000188:drug therapy* / Q000209:etiology; D020767:Intracranial Thrombosis / Q000188:drug therapy* / Q000209:etiology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab